PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsChina begins first CRISPR human therapy trial

BioNews

China begins first CRISPR human therapy trial

Published 25 November 2016 posted in News and appears in BioNews 878

Author

Anneesa Amjad

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Chinese scientists have injected CRISPR/Cas9 gene-edited cells into a human for the first time...

Chinese scientists have injected CRISPR/Cas9 gene-edited cells into a human for the first time.

The patient, who has non-small-cell lung cancer, received the modified cells as part of a clinical trial at the Sichuan University West China Hospital in Chengdu (see BioNews 861).

This is the first of several CRISPR clinical trials that are planned in China and in the US, all aimed at treating various cancers. The US trial, which will be funded by Facebook billionaire Sean Parker, is due to begin in 2017 at the University of Pennsylvania (see BioNews 857).

'I think this is going to trigger Sputnik 2.0, a biomedical duel on progress between China and the United States, which is important since competition usually improves the end product,' Professor Carl June, who will lead the US trial, told Nature News.

The team from China extracted immune T cells from the patient's blood, and used CRISPR/Cas9 to delete the gene that produces PD-1, a protein that keeps the immune response in check. PD-1 inadvertently helps cancerous cells as it tempers the response of T cells that would otherwise attack them. The modified cells were cultured and then injected back into the patient.

Oncologist Dr Lu You, who is leading the trial, said that the treatment went smoothly and the patient has been given a second injection. Each participant will receive between two and four injections in total. The focus of the clinical trial is to establish the safety of the technique, and all ten participants will be monitored closely.

Trials involving PD-1 antibodies, which would operate in the same way to take the brakes off the immune system have shown some promise. Dr Naiyer Rizvi of Columbia University Medical Centre, says he doubts whether the CRISPR-modified cells will work any better than the antibodies, which can be produced in unlimited numbers.

He told Nature News: 'It's an exciting strategy. The rationale is strong.' But he added that process of extracting, genetically modifying and multiplying cells is 'a huge undertaking and not very scalable'. 'Unless it shows a large gain in efficacy, it will be hard to justify moving forward,' he concluded.

On Wednesday 7 December 2017, genome editing and embryo research will be debated at the Progress Educational Trust's public conference 'Rethinking the Ethics of Embryo Research: Genome Editing, 14 Days and Beyond'.

Click here for full for full details, including the conference agenda and how to book your tickets, and email sstarr@progress.org.uk with any queries.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
2 November 2018 • 2 minutes read

Study suggests 96 percent of people 'immune' to CRISPR/Cas9

by Dr Eleanor Lynam

The genome editing system, CRISPR/Cas9, may not be as successful in humans as hoped...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
8 June 2018 • 2 minutes read

FDA puts major CRISPR genome editing trial on hold

by Christie Whitehouse

The US drugs regulator has put on hold an application for a clinical trial of a new genome editing based treatment for sickle cell disease...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
16 April 2018 • 2 minutes read

First genome-editing trial in Europe gets go-ahead

by Shaoni Bhattacharya

Europe's first clinical trial to use genome editing in humans has received approval to start later this year...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
31 August 2017 • 3 minutes read

CRISPR genome editing may cause unintended mutations

by Charlotte Spicer

CRISPR may introduce hundreds of unwanted mutations into the genome, a small study finds...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
31 August 2017 • 3 minutes read

Biotech companies criticise CRISPR mutation study

by Charlotte Spicer

Two major biotech companies have criticised a recent study that claimed CRISPR may cause hundreds of unwanted mutations...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 January 2017 • 2 minutes read

Chinese scientists to begin first human CRISPR trial

by Rachel Siden

Chinese scientists plan to start the first-ever clinical trial of CRISPR genome-editing technology in humans — on patients with lung cancer — this August...

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
14 November 2016 • 3 minutes read

Swedish scientist edits genomes of healthy human embryos

by Anneesa Amjad

A scientist in Sweden has become the first to edit genes in healthy human embryos...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
14 September 2016 • 3 minutes read

CRISPR cancer therapy trial gets go-ahead in US

by Rachel Reeves

The first in-human use of the genome-editing technology CRISPR has been approved by a US federal safety board...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Smokers develop 150 mutations per lung cell

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856